REGENERON PHARMACEUTICALS, INC. Dividends Paid
REGENERON PHARMACEUTICALS, INC. (REGN) reported Dividends Paid of $194.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDividends · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. payments of dividends for the quarter ending 2026-06-30 was $96.80M, a 4.54% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments of dividends for the quarter ending 2026-03-31 was $97.80M, a 4.26% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments of dividends for the quarter ending 2025-12-31 was $92.70M.
- REGENERON PHARMACEUTICALS, INC. payments of dividends for the quarter ending 2025-09-30 was $91.20M.
- REGENERON PHARMACEUTICALS, INC. payments of dividends for fiscal 2025 was $370.30M.
- REGENERON PHARMACEUTICALS, INC. payments of dividends for fiscal 2024 was $0.00.
- REGENERON PHARMACEUTICALS, INC. payments of dividends for fiscal 2023 was $0.00.
| Period end | Payments of Dividends 3 month | Payments of Dividends 6 month | Payments of Dividends 9 month | Payments of Dividends 12 month |
|---|---|---|---|---|
| 2026-06-30 | $96.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $194.60M 10-Q · filed 2026-07-30 | $287.30M derived: sum of 3 quarters · filed 2026-07-30 | $378.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $97.80M 10-Q · filed 2026-04-29 | $190.50M derived: sum of 2 quarters · filed 2026-04-29 | $281.70M derived: sum of 3 quarters · filed 2026-04-29 | $374.30M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $92.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $183.90M derived: sum of 2 quarters · filed 2026-02-04 | $276.50M derived: sum of 3 quarters · filed 2026-07-30 | $370.30M 10-K · filed 2026-02-04 |
| 2025-09-30 | $91.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $183.80M derived: sum of 2 quarters · filed 2026-07-30 | $277.60M 10-Q · filed 2025-10-28 | $277.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $92.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $186.40M 10-Q · filed 2026-07-30 | $186.40M derived: sum of 3 quarters · filed 2026-07-30 | $186.40M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $93.80M 10-Q · filed 2026-04-29 | $93.80M derived: sum of 2 quarters · filed 2026-04-29 | $93.80M derived: sum of 3 quarters · filed 2026-04-29 | $93.80M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $0.00 derived: sum of 2 quarters · filed 2026-02-04 | $0.00 derived: sum of 3 quarters · filed 2026-02-04 | $0.00 10-K · filed 2026-02-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $0.00 10-Q · filed 2025-08-01 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |